Immunotherapy in Lung Cancer | Specialty

The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.

Tomivosertib Development in Frontline NSCLC Ending After Findings from KICKSTART Trial

April 4th 2024

Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer.

Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC

March 25th 2024

Durvalumab/chemoradiation did not significantly improve survival vs chemoradiation alone in patients with unresectable non–small cell lung cancer.

FDA Grants Fast Track Designation to UV1 Cancer Vaccine for Unresectable/Metastatic Mesothelioma

February 5th 2024

The UV1 cancer vaccine received fast track designation for use in combination with ipilimumab and nivolumab for patients with unresectable malignant pleural mesothelioma.

Sequential Treatment With Telomere-Targeted Therapy, Checkpoint Inhibition Produces High DCR in NSCLC

January 18th 2024

Treatment with THIO followed by cemiplimab-rwlc led to a high DCR regardless of dose level in patients with pretreated non–small cell lung cancer.

European Commission Approves Subcutaneous Atezolizumab With Enhanze for Several Cancers

January 16th 2024

The European Commission granted marketing authorization for SC atezolizumab co-formulated with Enhanze for all approved indications of IV atezolizumab.

IO Combos Yield OS Advantage Vs Chemo Alone in Stage IV PD-L1–Negative NSCLC

November 11th 2023

As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.

Adjuvant Pembrolizumab Receives Positive CHMP Opinion for High-Risk NSCLC After Resection and Chemo

September 15th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of pembrolizumab as adjuvant treatment for adult patients with non–small cell lung cancer who are at high risk of recurrence following complete resection and platinum-based chemotherapy.

Subgroup Observations From Missed KEYNOTE-789 Data in NSCLC Provide Insight for the Future

September 4th 2023

James Chih-Hsin Yang, MD, PhD, discusses the implications of the phase 3 KEYNOTE-789 trial and what directions investigators can examine in the future to help fill the unmet need for patients with TKI-resistant, EGFR-mutated metastatic non–small cell lung cancer.

Data With TTFields Raise Questions Around the Future of Immunotherapy in Metastatic NSCLC

August 7th 2023

Tony S.K. Mok, MD, BMSc, FRCPC, FASCO, provides perspective on the use of tumor treating fields in lung cancer, the use of anti–PD-L1 inhibitors approved in China, and the potential impact of the microbiome on response with immunotherapy.

Practice Pearls for Community Oncologists Treating Early-Stage NSCLC

August 3rd 2023

A panel of experts share unmet needs and clinical practice pearls for community oncologists regarding the treatment of patients with early-stage NSCLC.

Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab

August 3rd 2023

Tina Cascone, MD, Ben Levy, MD, and Sandip Patel, MD, offer insights into the treatment approach in patients with unresectable early-stage NSCLC who are unsuitable for consolidation durvalumab or who progress on consolidation durvalumab.

Further Research May Delineate Immunotherapy Resistance Mechanisms in Lung Cancer

August 2nd 2023

Solange Peters, MD, PhD, discusses the successes and shortcomings of immunotherapy in patients with lung cancer; current challenges with defining resistance mechanisms to immunotherapy in this disease; and the potential applications of circulating tumor DNA monitoring in the early and metastatic disease settings.

Consolidation Immunotherapy in Unresectable Early NSCLC: Novel Approaches

July 28th 2023

Sandip Patel, MD, shares his expert perspectives on novel combination consolidation immunotherapy regimens that are under evaluation in unresectable early-stage NSCLC.

Perioperative Nivolumab Plus Chemo Improves pCR, Survival in Stage III NSCLC

July 28th 2023

Neoadjuvant treatment with nivolumab plus platinum-based chemotherapy followed by adjuvant nivolumab increased pathological complete response rates and prolonged survival compared with neoadjuvant chemotherapy alone in patients with resectable stage IIIA/B non–small cell lung cancer.

China’s NMPA Accepts sNDA for First-Line Toripalimab Plus Chemo in ES-SCLC

July 20th 2023

China’s National Medical Products Administration has accepted a supplemental new drug application seeking the approval of toripalimab in combination with platinum-based chemotherapy for the first-line treatment of patients with extensive-stage small cell lung cancer.

Consolidation Immunotherapy in Unresectable Early NSCLC: PACIFIC Study

July 20th 2023

Ben Levy, MD, reviews the 5-year update and clinical implications of the PACIFIC study which evaluated consolidation immunotherapy in unresectable early-stage NSCLC.

Treatment Strategy in Patients with Unresectable Stage I-III NSCLC

July 20th 2023

Expert panelists discuss the characterization of patients with unresectable, early-stage NSCLC and what their standard treatment approach is for this patient population.

Despite Diagnostic Challenges, ADCs Are Poised to Expand Treatment Options in Lung Cancer

July 13th 2023

As antibody-drug conjugates become an established part of the lung cancer treatment paradigm, identifying which patients will benefit the most from treatment with these highly specific agents remains a challenge for clinicians.

Adjuvant Therapy in NSCLC: IMPower-010 and KEYNOTE-091 Studies

July 13th 2023

Sandip Patel, MD, and Ben Levy, MD, discuss the results and clinical implications of the IMPower-010 and KEYNOTE-091 studies of adjuvant immunotherapy in NSCLC.

Neoadjuvant Versus Adjuvant Therapy in Resectable NSCLC

July 13th 2023

A panel of experts offers their insights into which patients with resectable early-stage NSCLC might be suitable for neoadjuvant versus adjuvant chemoimmunotherapy.